Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 205-440-9 | CAS number: 140-90-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- Single dose
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- guideline study with acceptable restrictions
- Justification for type of information:
- Old test report, but sufficient to conclude classification
Note that the large numbers of animals over an excessive number of dose levels was normal for that period in the US - Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- Deviations:
- not specified
- GLP compliance:
- not specified
- Remarks:
- This study predates the requirements for good laboratory practice, however the study was considered adequate for this assessment
- Species:
- mouse
- Strain:
- other: albino
- Sex:
- male
- Route of administration:
- oral: gavage
- Vehicle:
- not specified
- Doses:
- 500 - 5000 mg/kg single dose
- No. of animals per sex per dose:
- Up to 13 animals per dose group
- Control animals:
- not specified
- Sex:
- male
- Dose descriptor:
- LD50
- Effect level:
- 730 mg/kg bw
- Mortality:
- Yes. At dose levels of 750 mg/kg and above
- Clinical signs:
- other: The target organs for oral toxicity were the central nervous system, liver and spleen. The majority of death occurred on the first day, and the animals that survived appeared normal within two days
- Gross pathology:
- Depression followed by hyperexcitability, tremors, paralysis exophtaalmia and clonic followed by tonic convulsions.
Pinkness of feet and nose, preening and salivation. Consolidated lungs, pale granular livers, unusually small spleens and atonic intestine. Surviving animals showed no abnormalities - Interpretation of results:
- Category 4 based on GHS criteria
- Conclusions:
- Considered valid for classification is within expected values for the class of substance.
Other studies lead to same classification conclusions.
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 730 mg/kg bw
Acute toxicity: via inhalation route
Link to relevant study records
- Endpoint:
- acute toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- data from handbook or collection of data
- Justification for type of information:
- Data from review document on related substance to strengthen read-across for other endpoints
Original reference not found
Methods and details of results not described in detail, but were clearly considered acceptable for the Australian Government review - Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 403 (Acute Inhalation Toxicity)
- Deviations:
- not specified
- GLP compliance:
- not specified
- Remarks:
- Original 1982 study thought to pre-date universal GLP
- Test type:
- traditional method
- Limit test:
- no
- Species:
- rat
- Strain:
- not specified
- Sex:
- not specified
- Route of administration:
- inhalation
- Type of inhalation exposure:
- not specified
- Vehicle:
- not specified
- Duration of exposure:
- 2 h
- Control animals:
- not specified
- Dose descriptor:
- LC50
- Effect level:
- 7 690 mg/m³ air
- Clinical signs:
- other: Not specified in secondary source
- Interpretation of results:
- GHS criteria not met
- Remarks:
- Not considered acutely toxic by inhalation.
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LC50
- Value:
- 7 690 mg/m³ air
Acute toxicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
There is very little published and unpublished data available on the adverse health effects of xanthates in general and sodium ethyl xanthate in particular. Toxicological data for other xanthates were also assessed where available, as the adverse effects of the various xanthates are similar.
The acute oral toxicity study indicates that sodium ethyl xanthate as a 10% solution at a pH of 10.5 to 11 has an LD50 of 730 mg/kg in mice. The target sites are the central nervous system, liver and the spleen, similar to carbon disulphide. The oral LD50 for other xanthates in mice ranges from 411 to 583 mg/kg and in rats from 1000 to 2000 mg/kg.
Acute toxicity via oral route:
Effect level:
LD50= 730 mg/kg b.w. in male mice; as 10% water solution of sodium ethyl xanthate (CAS# 140-90-9)
LD50of various xanthates are similar, ranging from 411 to 583 mg/kg b.w. in mice and from 1000 to 2000 mg/kb b.w. in rats.
Oral administration of potassium butyl xanthate (CAS# 871-58-9) to rats produced increased motor activity , cyanosis, irritability , increased respiration and convulsions with death occurring 1 to 2 hours after administration. Autopsy shoved pervascular and pericellular oedema, multiple haemorrhages in the lungs perivascular subarachnoid heamorrhages and acute swelling of the cells of the cortex, subcortical ganglia and brain stem. Also were observed fatty dystrophy of the liver and protein dystrophy of the kidney
PubliFull Public Report, Sodium Ethyl Xanthate, Priority Existing Chemical No. 5 , May 1995, Canberra , Australia
After ingestion of CS2, CAS# 75-15-0) victims exhibited spasmodic tremors, prostration, dyspnea, cyanosis, peripheral vascular collapse, hypothermia, mydriasis, convulsions, coma and death in few hours from respiratory paralysis. Only mild gastrointestinal irritation and visceral congestion were noted at autopsy. Women appear to be more sensitive than men to the neurotoxic effects of carbon disulfide. Industrially exposed workers have exhibited neuropsychiatric disorders ranging from irritability to manic-depressive psychosis, clinical manifestations of nerve damage are blindness, and signs of parkinsonism.
(Toxicological Profile for carbon disulfide. U.S. Department of Health and Human Services . Public Health Service . Agency for Toxic Substances and Disease Registry . August 1996)
Acute toxicity via inhalation route:
Depending upon the concentration of CS2in repairable air different types of poisoning symptoms are encountered. Most prominent are general neurotoxic and narcotic effects.
NOEC: 500 - 700 mg/m3(160 - 224 ppm) of CS2
2500mg/m3= 800 ppm for 1.5 - 3 hours: strong headache,
6400 - 10000mg/m3(2048 - 3200 ppm) for 30min. narcotic condition, strong headache. (IUCLID Dataset: Carbon Disulfide, Creation date 19 February 2000, European Commission, European Chemicals Bureau)
An inhalation maximum risk level (MRL) 0.3 ppm (0.9mg/m3) for CS2was derived based on epidemiological data, concerning public health.
LOAEL= 7.6 ppm, represents the average exposure of workers 8 hour/day, 5 days a week for a mean exposure period of 12 years(ATSDR 1996, Toxicological profile for carbon disulfide. Atlanta, GA, US Department of Health and Human Services, Research Triangle Institute Contract No. 205-93-0606).
Acute toxicity via dermal route:
Application of 1 gm/kg of sodium ethyl xanthate in the form of a paste resulted in the death of ten out of twelve animals within 24 hrs. The surviving animals developed irritant effects including oedema and pigmentation of the skin. The sulphide odour noted during the study suggests that decomposition of sodium ethyl xanthate occurred. The dermal LD50 was < 1000 mg/kg.
Sodium ethyl xanthate (CAS# 140-90-9)or sodium isobutyl xanthate (CAS # 25306-75-6) can be assessed as a substances strongly irritating skin of rabbits – IIPC factor accordingly 6.2 and 7.0.(The Institute of Organic Industry Branch of Pszczyna Toxicology Department, March 1998)
Sodium or potassium xanthates dissolved in water undergoes hydrolysis giving alkaline reaction. When xanthates are produced as a water solutions exes of alkali hydroxide is kept (pH >10) as a decomposition inhibitor.
Human information
Xanthates dust or mist from solution cause irritation to the nose, throat and upper respiratory tract. The solids give carbon disulfide in contact with water, very toxic and extremely flammable vapour. Relatively low concentration of carbon disulfide can harm the central nervous system, may cause headache , dizziness, fatigue, excitement and depression. High concentration of CS2can cause psychological disturbances and death.
It is known one case reported of acute exposure of an employee who lost consciousness when was opened a tank containing powder sodium ethyl xanthate. The worker was restless, vomited and had convulsive twitching of muscles in arms and legs. He complained of difficulty breathing, eye tearing and hoarseness. the respiratory and eye effects persisted for 3 weeks. No toxic effects were observed 3 month later.(COOH, CHEMINFO Sodium ethyl xanthateupdated July 2010,www.ccohs.ca)
Probable the oral lethal human dose of sodium ethyl xanthate is between 50-500mg/kg(Gosselin R.E., Hodge H.C., Smith R.P., Gleason M.N., Clinical Toxicology of Commercial Products,1979.,p. II-211)
An assessment of acid or alkali reserve
Sodium or potassium xanthates dissolved in water undergoes hydrolysis giving alkaline reaction. When xanthates are produced as a water solutions exes of an alkali hydroxide is kept (pH >10) as a decomposition inhibitor.
Respiratory tract
Sodium isopropyl xanthate(CAS# 140-93-2) irritating to skin, eyes, mucous membrane, respiratory tract(The Merck Index , 9th ed., Merck & Co., Inc., 1976 , p. 1116; http:// toxnet.nlm.nih.gov/cgi-bin/sis/search/f?./temp )
Xanthates dust or water solution mist is irritating to the nose, throat and upper respiratory track under normal condition of use.(COOH, CHEMINFO Sodium ethyl xanthate updated July 20210,www.ccohs.ca)
Sodium isopropyl xanthate(CAS# 140-93-2)is irritating to skin, eyes, mucous membrane, respiratory tract(The Merck Index , 9th ed., Merck & Co., Inc., 1976 , p. 1116; http:// toxnet.nlm.nih.gov/cgi-bin/sis/search/f?./temp )
Justification for classification or non-classification
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.